期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

舒尼替尼联合放疗治疗1例肾癌脑多发转移并文献复习

下载PDF
导出
摘要 近年来,随着肾癌发病分子机制的深入研究,多种治疗晚期肾癌的分子靶向药物相继问世,很大程度上提高了晚期肾癌患者的总缓解率,并延长其中位无疾病进展生存期（PFS）。多靶点的小分子酪氨酸激酶抑制剂——舒尼替尼在一线、二线治疗晚期转移性肾恶性肿瘤中取得显著疗效[1]。有研究表明,舒尼替尼能够穿透血-脑脊液屏障到达颅内发挥抗肿瘤效应[2]。因此,舒尼替尼是否可用于肾癌脑转移的治疗备受关注。
作者 吴晶晶 张妍 林城 黄于芳 陈雄
机构地区 南京军区福州总医院肿瘤科 厦门大学福总临床医学院 福建中医药大学福总教学医院肿瘤科 福建医科大学福总临床医学院
出处 《实用肿瘤杂志》 CAS 2015年第1期82-84,共3页 Journal of Practical Oncology
关键词 脑肿瘤/放射疗法 脑肿瘤/药物疗法 脑肿瘤/继发性 肾肿瘤/药物疗法 肿瘤转移 蛋白酪氨酸激酶类/拮抗剂和抑制剂 蛋白酪氨酸激酶类/治疗应用 病例报告
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1马建辉.晚期肾癌靶向治疗临床研究现状[J].实用肿瘤杂志,2010,25(3):257-260. 被引量：10
  • 2Patyna S, Haznedar J, Morris D, et al. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetaldevelopment in rats and rabbits [ J ]. Birth Defects Res B Dev Reprod Toxicol,2009,86(4) :204 - 213.
  • 3Weight C J, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical Tlb renal tumors is associated with improved overall survival [ J ]. Urology, 2010,76(3) :631 -637.
  • 4王莹,李真,宋鑫.转移性肾癌靶向治疗研究新进展[J].实用肿瘤杂志,2013,28(6):569-574. 被引量：7
  • 5Culine S, Bekradda M, Kramar A, et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma [ J ]. Cancer, 1998,83 ( 12 ) :2548 - 2553.
  • 6Motzer ILl, Hutson TE, Tomczak P, et al. Overall servival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Onco1,2009,27 ( 22 ) :3548 - 3590.
  • 7Caffo M, Barresi V, Caruso G, et al. Innovative therapeutic strategies in the treatment of brain metastases [ J ]. Int J Mol Sci,2013,14( 1 ) :2135 -2174.
  • 8Wronski M, Arbit E, Russo P, et al. Surgical resection of brain metastases from renal cell carcinoma in 50 patients [ J ]. Urology, 1996,47 (2) : 187 - 193.
  • 9Yun OH, David J. Stewart Systemic therapy for lung cancer brain metastases : a rationale for clinical trials [ J ]. Oneology,2008,22(2) : 168 - 168.
  • 10Mima T,Toyonaga S,Mori K, et al. Early decrease of P- glycoprotein in the endothelium of the rat brain capillarise after moderate dose of irradiation [ J ]. Neurol Res, 1999,21 ( 2 ) : 209 - 209.

二级参考文献70

  • 1Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [ J ]. N Engl J Med,2007,356(2) :125 - 134.
  • 2Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma : Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial [ J]. J Clin Oncol,2009,27 (20) :3312 -3318.
  • 3Knox J, Figlin R, Stadler W, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America:Safety and efficacy [ J ]. J Clin Oncol,2007,25(18S) :5011.
  • 4Escudier B, Szczylik C, Hutson T E, et al. Randomized phase H trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma [ J]. J Clin Onco1,2009,27 (8) : 1280 - 1289.
  • 5Motzer R J, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma [J]. JAMA, 2006,295 (21) :2516 - 2524.
  • 6Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [ J ]. N Engl J Med ,2007,356 (2) : 115 - 124.
  • 7Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma [ J ]. J Clin Oncol, 2009,27 ( 22 ) : 3584 - 3590.
  • 8Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial [ J ]. Lancet Oncol, 2009,10 ( 8 ) : 757 - 763.
  • 9Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double- blind phase III trial[J]. Lancet, 2007,370 (9605) : 2103 -2111.
  • 10Escudier B J, Bellmunt J, Negrier S,et al. Final results of the phase III, randomised, double-blind AVOREN Trial of First-line bevacizumab (BEV) + interferon-alpha2a (IFN) in metastatic renal cell carcinoma(mRCC) [ J ]. J Clin Oncol ( Meeting Abstraacts), 2009,27 : Abstraacts5020.

共引文献15

实用肿瘤杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部